Overview of the Vioxx (Rofecoxib) Cardio-Renal Related Adverse Medical Events ~ OPOLAW Injury Blog

Thursday, January 29, 2009

Overview of the Vioxx (Rofecoxib) Cardio-Renal Related Adverse Medical Events

Vioxx Background Vioxx was approved by the U.S. Food and Drug Administration in May 1999. It is marketed as 12.5 mg, 25 mg and 50 mg tablets and as an oral suspension. It is also available in 73 other countries. Merck estimates that 13 and 24 million patients have been prescribed the drug in the U.S. and worldwide, respectively. U.S. Vioxx sales exceeded $2.5 billion in 2001. Vioxx is classified as a nonsteroidal anti-inflammatory drug (NSAID or NANSAID) with anti-inflammatory, analgesic and antipyretic properties. As such, it is indicated for pain, dysmenorrhea, osteoarthritis and rheumatoid arthritis. The earlier marketed NSAID products (i.e., ibuprofen, naproxen, etc.) are approved for similar indications, but are associated with greater (in frequency and severity) gastrointestinal-related adverse medical events. Next>> The Cyclooxygenase Enzymes If you think you may be suffering from side effects caused by a defective drug call an attorney at Owen, Patterson & Owen for assistance. We are an experienced law firm that can help you in protecting your legal rights and holding negligent parties responsible.
Click Here for a Free Case Assessment

No comments:

Post a Comment